1. Aggarwall, B. B., Eessalu, T. E., Hass, P. E. Characterization of receptors for human tumor necrosis factor and their regulation by γ-interferon. Nature. 318, 665. 1985.
2. Ahre, A., Bjorkholm, M., Mellstedt, H. H., Holm, G., Brenning, G., Engstedt, L., Gahrton, G., Hällen, J., Johansson, B., Johansson, S. G., Karnström, L., Killander, A., Lesner, R., Lockner, D.,Lönnquist,B.,Sinmonson,B., Stalfelt, A. M., Ternstedt, B., Wadman, B. Intermittent high dose melphalan/prednisone versus continuous low dose melphalan treatment in multiple myeloma. Eur. J. Cancer Clin. Oncol. 19, 499. 1983.
3. Ahre, A., Björkholm, M., Mellstedt, H., Brenning, G., Engstedt, L., Gahston, G., Gallenhammar, H., Holm, G., Johansson, B., Jônmark, M., Karnström, L., Killander, A., Lerner, R., Lockner, D., Lönnquist, B., Nilsson, B., Simonsson, B., Stalfelt, A. M., Strander, H., Svedmyr, E., Wadman, B., Wedelin, C. Human leukocyte interferon and intermittent high-dose Melphalan-Prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the myeloma group of central Sweden. Cancer. 68, 1331. 1984.
4. Alberts, D. S., Chang, S. Y., Chen, H. S. Variability of melphalan (M) absorption in man. Proc. Am. Assoc. Cancer Res. Am. Soc. Clin. Oncol. 19, 334. 1978.
5. Alexanian, R., Bergsagel, D. E., Migliore, P., Vaughn, W. K., Howe, C.D. Melphalan therapy for plasma cell myeloma. Blood. 31, 1. 1968.